DOI:
10.1055/s-00000045
Der Nuklearmediziner
LinksClose Window
References
Hofman MS, Emmett L, Sandhu SK. et al.
TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). J Clin Oncol.
2020
38. (suppl; abstr 5500)
Access:
We do not assume any responsibility for the contents of the web pages of other providers.